Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22241106 | 1.00 | USP2 (0.46) | USP2SMN1; SMN2EPHX2GPR119RECQL | |
| SCHEMBL6635995 | 0.86 | USP2 (0.46) | USP2SMN1; SMN2EPHX2GPR119RECQL | |
| SCHEMBL24013325 | 0.82 | USP2 (0.43) | USP2SMN1; SMN2EPHX2GPR119RECQL | |
| SCHEMBL31382304 | 0.82 | NAMPT (0.47) | USP2SMN1; SMN2EPHX2GPR119RECQL | |
| SCHEMBL31585987 | 0.81 | USP2 (0.46) | USP2SMN1; SMN2EPHX2GPR119RECQL | |
| SCHEMBL23265913 | 0.81 | TSHR (0.45) | USP2SMN1; SMN2RECQLKDM4EMAPT | |
| SCHEMBL22305158 | 0.80 | USP2 (0.49) | USP2SMN1; SMN2EPHX2GPR119RECQL | |
| SCHEMBL21927065 | 0.80 | CYP1A2 (0.43) | USP2SMN1; SMN2EPHX2GPR119NAMPT | |
| SCHEMBL22241124 | 0.79 | NAMPT (0.43) | USP2SMN1; SMN2EPHX2GPR119NAMPT | |
| SCHEMBL1555865 | 0.79 | USP2 (0.59) | USP2SMN1; SMN2EPHX2GPR119RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4282416-A2 | PROCESS OF MANUFACTURE OF A COMPOUND FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-20210346375-A1 | PROCESS OF MANUFACTURE OF A COMPOUND FOR INHIBITING THE ACTIVITY OF SHP2, AS WELL AS PRODUCTS RESULTING FROM ACID ADDITION | NOVARTIS AG (CH) | 2021-11-11 | — | — | US | disclosed |
| EP-3753941-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Blueray Biopharma Co., Ltd. (CN) | 2020-12-23 | — | — | EP | disclosed |
| WO-2020072656-A1 | IMIDOZOPYRIMIDINE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346375-A1 | PROCESS OF MANUFACTURE OF A COMPOUND FOR INHIBITING THE ACTIVITY OF SHP2, AS WELL AS PRODUCTS RESULTING FROM ACID ADDITION | PTPN5, PTPN7, PTPN1 | USP2 2291/4885SMN1; SMN2 3575/4885EPHX2 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.